FDA Approves Osimertinib with Platinum-Based Chemotherapy for EGFR-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from the FLAURA 2 study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Evidence for efficacy is based on the results from the FLAURA 2 study
Findings from the RENOBATE study
Findings from a multicentre cohort study
Conversion to traditional approval is based on an additional patients and an added follow-up time to assess duration of response in the VISION study
Findings from the HUDSON study
Findings from an exploratory preplanned biomarker analysis of the PARADIGM study
Evidence for efficacy is based on the results from the NAPOLI 3 study
Findings from the OCTANE analysis
Findings from the EORTC LCG-163 APPLE study
It is intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy
Findings from a dose-escalation phase I study
Findings from the Trans-Atlantic Pancreatic Surgery Consortium study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.